Forge Therapeutics is a San Diego-based biotechnology startup focused on developing antibiotics to treat lung infections. The company is working on antibiotic candidates aimed at respiratory infections. In January 2019 the company announced funding commitments totaling $11.1M from CARB-X. According to the announcement, Forge will initially receive $5.7M from CARB-X. CARB-X is described in the article as a public-private investor that funds projects targeting antibiotic-resistant bacteria. Forge Therapeutics discovers and develops small-molecule antibiotics that inhibit metalloenzymes in multi-drug resistant Gram-negative bacteria. Its proprietary chemistry approach is used to design inhibitors of zinc-dependent metalloenzymes, with a lead program against LpxC, an enzyme essential for Gram-negative bacterial growth. The company intends to advance its LpxC inhibitor into clinical studies. Forge is led by CEO Zachary A. Zimmerman, Ph.D. The company completed a financing to support near-term clinical advancement of its lead candidate. The business focuses on addressing the global health threat posed by so-called 'superbugs.'

Total raised

$26M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2019